Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Clinical Trial

Study Details

Enrollment

20

Interventions

Description

Defibrotide 6.25 mg/kg IV q6h up to 7 days

Name

Defibrotide

Type

Drug

Phase

Phase 2

Status

COMPLETED

Study ID #

NCT03805581

Study Type

Interventional

Summary

This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).

Study Overview

Conditions

Sickle Cell Disease

Acute Chest Syndrome

Contacts and Locations

Locations

Facility

New York Medical College
Valhalla, New York 10595
United States

GeoPoint

41.07482, -73.77513